A Phase 1a, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of the Safety, Tolerability and Pharmacokinetics of PMN310 Infusions in Healthy Volunteers
Latest Information Update: 04 Nov 2024
At a glance
- Drugs PMN 310 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; First in man
- Sponsors ProMIS Neurosciences
Most Recent Events
- 30 Oct 2024 According to a ProMIS Neurosciences media release, the Company presented positive results from all five cohorts from the Phase 1a, single ascending dose clinical trial of its lead product candidate, PMN310, at the 17th Clinical Trials on Alzheimer's Disease (CTAD) Conference on Wednesday, October 30 in Madrid, Spain.
- 30 Oct 2024 Results presented in the ProMIS Neurosciences Media Release.
- 12 Sep 2024 According to a ProMIS Neurosciences media release, the Company expects to report topline results from all five cohorts [in the coming months].